ASGN (ASGN Incorporated)
Insider Trading Activity
Every open-market purchase and sale reported by ASGN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-16 | Edwin A. Sheridan | Director | G | — | — |
| 2026-03-05 | Sadasivam Iyer | President | F | — | — |
| 2026-01-12 | JONATHAN S HOLMAN | Director | J | — | — |
| 2026-01-06 | Joseph Wendell Dyer | Director | A | — | — |
| 2026-01-06 | JONATHAN S HOLMAN | Director | MIXED | — | — |
| 2026-01-06 | Rose Cunningham | Chief Accounting Officer | MIXED | — | — |
| 2026-01-06 | ARSHAD MATIN | Director | MIXED | — | — |
| 2026-01-06 | Marie Perry | Exec VP, CFO | MIXED | — | — |
| 2026-01-06 | Jennifer Hankes Painter | SVP, Chief Legal Officer | MIXED | — | — |
| 2026-01-06 | Mark A. Frantz | Director | A | — | — |
| 2026-01-06 | MARIA R HAWTHORNE | Director | MIXED | — | — |
| 2026-01-06 | Carol Lindstrom | Director | A | — | — |
| 2026-01-06 | Theodore S. Hanson | CEO | MIXED | — | — |
| 2026-01-06 | Sadasivam Iyer | President | A | — | — |
| 2026-01-06 | Brian J. Callaghan | Director | A | — | — |
| 2026-01-06 | Edwin A. Sheridan | Director | A | — | — |
| 2026-01-06 | Patricia L Obermaier | Director | MIXED | — | — |
| 2025-06-13 | Patricia L Obermaier | Director | F | — | — |
| 2025-03-05 | Sadasivam Iyer | President | A | — | — |
| 2025-02-10 | Rose Cunningham | Chief Accounting Officer | MIXED | — | — |
| 2025-02-10 | RANDOLPH C BLAZER | President | MIXED | — | — |
| 2025-02-10 | Theodore S. Hanson | CEO | MIXED | — | — |
| 2025-02-10 | Jennifer Hankes Painter | SVP, Chief Legal Officer | MIXED | — | — |
| 2025-02-10 | Marie Perry | Exec VP, CFO | MIXED | — | — |
| 2025-01-08 | JONATHAN S HOLMAN | Director | J | — | — |
| 2025-01-06 | Joseph Wendell Dyer | Director | MIXED | — | — |
| 2025-01-06 | Theodore S. Hanson | CEO | MIXED | — | — |
| 2025-01-06 | ARSHAD MATIN | Director | MIXED | — | — |
| 2025-01-06 | JONATHAN S HOLMAN | Director | MIXED | — | — |
| 2025-01-06 | Patricia L Obermaier | Director | MIXED | — | — |
| 2025-01-06 | Jennifer Hankes Painter | SVP, Chief Legal Officer | MIXED | — | — |
| 2025-01-06 | Carol Lindstrom | Director | A | — | — |
| 2025-01-06 | MARIA R HAWTHORNE | Director | MIXED | — | — |
| 2025-01-06 | Brian J. Callaghan | Director | A | — | — |
| 2025-01-06 | Mark A. Frantz | Director | A | — | — |
| 2025-01-06 | RANDOLPH C BLAZER | President | MIXED | — | — |
| 2025-01-06 | Rose Cunningham | Chief Accounting Officer | MIXED | — | — |
| 2025-01-06 | Edwin A. Sheridan | Director | A | — | — |
| 2025-01-06 | Marie Perry | Exec VP, CFO | MIXED | — | — |
| 2024-11-14 | Theodore S. Hanson | CEO | Sell | — | — |
| 2024-10-25 | Carol Lindstrom | Director | Sell | — | — |
| 2024-10-25 | RANDOLPH C BLAZER | President | Sell | — | — |
| 2024-09-13 | ARSHAD MATIN | Director | Sell | — | — |
| 2024-09-11 | JONATHAN S HOLMAN | Director | Sell | — | — |
| 2024-08-23 | RANDOLPH C BLAZER | President | Sell | — | — |
| 2024-06-17 | MARIEL A JOLIET | Director | F | — | — |
| 2024-06-17 | Rose Cunningham | Chief Accounting Officer | F | — | — |
| 2024-06-17 | MARTY R KITTRELL | Director | F | — | — |
| 2024-05-06 | RANDOLPH C BLAZER | President | Sell | — | — |
| 2024-04-30 | MARTY R KITTRELL | Director | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | CEO | 424,561 | — |
| — | Director | 331,527 | — |
| — | Chief Executive Officer | 267,353 | — |
| — | — | 193,754 | — |
| — | SVP, CAO & Treasurer | 179,706 | — |
| — | President, Vista Staffing | 167,904 | — |
| — | President | 105,324 | — |
| — | — | 105,079 | — |
| — | Pres, Euro Life Sciences Div. | 95,763 | — |
| — | Exec VP, CFO | 86,146 | — |
| — | SVP, Chief Legal Officer | 76,125 | — |
| — | President, ECS | 69,774 | — |
| — | President, Healthcare & CSO | 65,128 | — |
| — | President | 59,070 | — |
| — | Director | 55,695 | — |
| — | Exec VP, CFO | 55,307 | — |
| — | Director | 46,987 | — |
| — | Senior Vice President | 30,639 | — |
| — | Director | 27,485 | — |
| — | Director | 18,201 | — |
| — | President, Nurse Travel | 17,978 | — |
| — | Director | 17,069 | — |
| — | Director | 16,157 | — |
| — | President of Vista Staffing | 16,070 | — |
| — | Chief Accounting Officer | 15,300 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ASGN quote page; the site-wide leaderboard is on the insider transactions hub.